XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Sale of Future Royalties - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2024
Sep. 30, 2022
Oct. 31, 2021
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jan. 01, 2021
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Collaboration revenue       $ 22,263,000 $ 10,971,000 $ 50,034,000 $ 18,150,000    
Liability related to sale of future royalties       331,361,000   331,361,000   $ 353,426,000  
Non-cash interest expense       $ 19,606,000 10,953,000 $ 37,667,000 17,270,000    
Jemperli Royalty Monetization Agreement                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Net of proceeds     $ 299,500,000            
Effective interest rate (as a percent)       28.90%   28.90%      
Non-cash interest expense and amortization of issuance costs       $ 19,300,000 10,700,000 $ 37,200,000 16,800,000    
Non-cash interest expense           37,106,000      
Jemperli Royalty Monetization Agreement | Sagard                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Proceeds from sale of future royalties     250,000,000            
Royalties and milestones received       121,500,000   121,500,000      
Issuance costs related to the sale of future royalties     400,000            
Jemperli Royalty Monetization Agreement | Sagard | By the end of 2026                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Royalties and milestones, agreement amount to be received     600,000,000            
Jemperli Royalty Monetization Agreement | Sagard | During 2027                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Royalties and milestones, agreement amount to be received     675,000,000            
Jemperli Royalty Monetization Agreement | GSK                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Collaboration revenue       21,100,000 10,100,000 38,400,000 16,300,000    
Zejula Royalty Monetization Agreement                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Issuance costs related to the sale of future royalties   $ 200,000              
Net of proceeds   34,800,000              
Non-cash interest expense           491,000      
Zejula Royalty Monetization Agreement | GSK                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Collaboration revenue       1,100,000 900,000 2,000,000 1,900,000    
Settlement agreement rate (as a percent)                 0.50%
Non-cash interest expense       $ 300,000 $ 200,000 $ 500,000 $ 400,000    
Zejula Royalty Monetization Agreement | DRI Healthcare Trust                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Proceeds from sale of future royalties   35,000,000              
Royalties and milestones, agreement amount to be received   10,000,000              
Liability related to sale of future royalties   $ 35,000,000              
Jemperli Royalty Monetization Agreement Amendment 1 | Sagard                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Proceeds from sale of future royalties $ 50,000,000                
Issuance costs related to the sale of future royalties $ 100,000                
JEMPERLI Royalty Monetization Agreement | Sagard                  
Liabilities Related To Sale Of Future Royalties [Line Items]                  
Rights retained     75,000,000            
Royalties agreement, maximum annual royalty payout capacity     $ 1,000,000,000